Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently completed a Phase 3 clinical ...

在涉及407名不可切除或转移性黑色素瘤患者的关键第3期试验中，联合疗法实现的中位无进展生存期为19.4个月，而pembrolizumab单药治疗为11.0个月 (HR=0.77，p=0.056)。

纽约 - 市值为1.19亿美元的临床阶段生物技术公司IO Biotech (NASDAQ: IOBT )将于周一美国东部时间上午8:30 (北京时间20:30)举行电话会议和网络直播，公布其关键性三期试验的初步结果。该试验研究Cylembio联合pembrolizumab用于晚期黑色素瘤治疗。该公司股票表现波动显著，过去一周下跌18%，而六个月内上涨近100%。 InvestingPro ...

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

All received pembrolizumab followed by a second cycle + RT (anti-PD1/RT) of 24 Gy/three daily fractions delivered to the breast tumor and then neoadjuvant chemotherapy (NAC). Blood and tumor biopsies ...

The IO Biotech management team will host a webcast/conference call on Monday, August 11, 2025, at 8:30 a.m. ET to discuss the topline results from the Phase 3 trial of Cylembio. Those who would like ...

Pembrolizumab conferred a small but statistically significant survival benefit when added to best supportive care as second-line treatment for patients with advanced hepatocellular carcinoma ...

Background: Relapse after surgery for high-risk clear cell RCC (ccRCC) is associated with shortened life expectancy. Effective perioperative therapy to reduce this risk remains an unmet need. Adjuvant ...